Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 17Sarcoma 13Lymphoid 11Gynecologic 9CNS 6Tumor-Agnostic 4Other hematologic neoplasm 4Breast 4Head & Neck 3Gastrointestinal 3Dermatologic 3Thoracic 2Plasma cell 1Other solid neoplasm 1

Conditions

Neoplasms 3Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × temsirolimus × Tumor-Agnostic × Clear all
NCT00838539 2018-09-18

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
63 enrolled 26 charts
Tumor-Agnostic

Neoplasms

NCT01378377 2018-07-30

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

EMD Serono

Phase 1 Terminated
33 enrolled 21 charts
Tumor-Agnostic

Neoplasms

NCT01009203 2015-08-10

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

New Mexico Cancer Research Alliance

Phase 2 Terminated
13 enrolled 8 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT00106353 2013-02-08

Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Pfizer

Phase 1/2 Completed
71 enrolled 42 charts
Tumor-Agnostic

Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡